Georg-Speyer-Haus. Foto: Andreas Reeg, Research for Life
Georg-Speyer-Haus. Foto: Andreas Reeg,
Georg-Speyer-Haus. Foto: Andreas Reeg,
Georg-Speyer-Haus. Foto: Andreas Reeg,

ERC Advanced Grant 2021 for PLASTICITY

Director Prof. Dr. Florian Greten again receives the highest EU science award for his colorectal cancer research and for the development of new therapeutic approaches. The project Cell Plasticity in Metastatic Colorectal Cancer – PLASTICAN will be funded with 2.5 million EUR for the next 5 years. Read more ->

Certificate for HR policy

GSH and 68 other employers have been certified by the audit berufundfamilie for their strategic design of a family- and life-phases-conscious HR policy. Outstanding family management is especially important in times of crisis. Read more -> 

Dr. Medyouf participates in EU ITN INTERCEPT-MDS

The research focus of the EU-funded INTERCEPT-MDS project is on myeloid blood cancers and the latest methods of single cell technology to develop innovative research tools for the identification of clonally different cells. In addition, the network unites European expertise in epigenetics and chromatin regulation to specifically identify diseased cells. In doing so, the clinical treatment of diseased cells could be improved in the future using methods of interceptive medicine. Read more ->

Page 1 of 4.

1 2 3 4

ERC Advanced Grant 2021 goes to Prof. Dr. Greten

Great Award for Director of the Georg-Speyer-Haus Frankfurt am Main, April 22, 2021 – The European Research Council (ERC) is funding a project by Prof. Dr. Florian R. Greten with a prestigious Advanced Grant. Prof. Greten is director of the Georg-Speyer-Haus (GSH), Institute for Tumor Biology and Experimental Therapy, and speaker of the LOEWE -… [mehr]

1st certificate for GSH HR strategy

GSH receives audit berufundfamilie certificate For the first time, Georg-Speyer-Haus received the audit berufundfamilie certificate for the strategic design of its family- and life-phase-conscious personnel policy. The certificate, that is considered a label of quality for a company compatibility policy, is awarded by the board of trustees of berufundfamilie Service GmbH under the German Federal… [mehr]

Dr. Medyouf participates in EU ITN INTERCEPT-MDS

Dr. Medyouf participates in the European Innovative Training Network INTERCEPT-MDS focusing on the shared training and research in Myeloid Diseases.   Dr. Medyouf’s team will participate in the European Innovative Training Network (ITN) INTERCEPT-MDS, a Marie Skłodowska Curie Action, funded by the European Commission under H2020 framework programme, and coordinated by Dr. Marcus Buschbeck at… [mehr]

New EU research consortium with participation of GSH

The EUbOPEN consortium (Enabling and Unlocking Biology in the OPEN) aims to generate a comprehensive pharmacological drug library and make it accessible to the research community. The EU project of the Innovative Medicines Initiative (IMI2), which is funded for 5 years, is a collaboration of 22 institutions and pharmaceutical companies. At GSH, active ingredients are… [mehr]

Beug Foundation Research Award for Dr. Sevenich on metastasis research

This year's 2019 Beug Foundation Metastasis Research Award goes to Dr. Lisa Sevenich for her efforts in studying T-cell responses in brain metastases. "I am very honored by this award. The grant from the Beug Foundation will allow us to study new types of aspects of the complex interactions between tumor cells and immune cells… [mehr]

Prof. Dr. Krause receives project funding from EKFS

Else Kroener-Fresenius-Foundation funds research project of Prof. Dr. Daniela Krause The main focus of the research group headed by Prof. Dr. Daniela Krause is the extracellular matrix in the bone marrow to improve normal and inhibit malignant blood formation. The funding by the EKF Foundation enables the lab unit of Prof. Dr. Krause to investigate… [mehr]

Extention DFG research group for colorectal cancer

Cell Plasticity in Colorectal Carcinogenesis research group under leadership of Prof. Dr. Greten receives extension for additional 3 years   Colorectal cancer is the second leading cause of death among cancers in men and women. Although there have been advancements in diagnosis, therapy in patients with metastases has only been successful in a few patients… [mehr]

Fighting Colorectal Cancer with Killer Cells

Scientists have shown for the 1st time in mini-tumors from the lab that genetically modified defense cells can successfully destroy colon cancer cells. Dabei setzen die Wissenschaftler am GSH auf einen die neue Krebsimmuntherapie mit genmodifizierten natürlichen Killerzellen. Mit den patientenspezifischen Tumorkulturen können Wissenschaftler jetzt im Labor prüfen, wie gut diese bei einzelnen Patienten anschlagen.… [mehr]

Colorectal cancer: Local mediator sets colon cells onto wrong track

Die Signalmoleküle der Wnt-Familie gehören zu den wichtigsten Botenstoffen, damit sich unsere stark beanspruchte Darmschleimhaut fortwährend erneuern kann. Jedoch sind zu viele Wnt häufiger Auslöser für Darmkrebs. Wnt gilt deshalb als wichtiger Biomarker und therapeutischer Angriffspunkt. Welche zelluläre Antwort durch Wnt ausgelöst wird, kann bei Darmkrebspatient*innen einen günstigen oder schlechten Krankheitsverlauf anzeigen. In etwa 80 Prozent… [mehr]

Page 1 of 4.

1 2 3 4